生物标志物能否助力难治性哮喘达标治疗?
本文综述难治性哮喘生物标志物的现有证据,涵盖指导传统与新型靶向治疗、评估吸入和口服糖皮质激素依从性(如泼尼松龙与皮质醇检测、呼出气一氧化氮抑制试验)以及2型炎症标志物(痰和外周血嗜酸性粒细胞、呼出气一氧化氮、血清IgE、骨膜蛋白)。不同标志物反映2型炎症通路的不同组分,非2型炎症难治性哮喘的标志物研究进展有限。未来方向包括发现新标志物、直接测量细胞因子及联合使用标志物。
要点
- 生物标志物有望指导难治性哮喘传统及靶向治疗的选择与疗效判断。
- 泼尼松龙/皮质醇检测和呼出气一氧化氮抑制试验有助于评估激素依从性。
- 不同2型炎症标志物反映不同通路组分,非2型炎症标志物进展有限。
核心结论
- 生物标志物在难治性哮喘的精准管理中具有潜力,但需提供辅助临床决策的有用信息而非仅增加检测项目。
研究设计与样本
- 综述,总结难治性哮喘生物标志物指导传统和新型靶向治疗及评估依从性的现有知识。
主要发现
- 泼尼松龙和皮质醇检测及呼出气一氧化氮抑制试验在评估吸入和口服糖皮质激素不依从方面显示前景。
- 痰和外周血嗜酸性粒细胞、呼出气一氧化氮、血清IgE和骨膜蛋白等2型炎症标志物可潜在指导难治性2型炎症干预选择及判断疗效。
- 不同生物标志物反映复杂2型炎症通路的不同组分。
- 非2型炎症相关难治性哮喘的生物标志物研究进展较少。
临床怎么用
- 可利用泼尼松龙/皮质醇检测和呼出气一氧化氮抑制试验评估激素不依从。
- 选择新型靶向干预及判断疗效时可参考2型炎症标志物,但需认识其反映通路组分的差异。
局限性
- 非2型炎症难治性哮喘缺乏可用生物标志物。
- 生物标志物需证明能辅助临床决策而非仅增加检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biomarkers may be a key foundation for the precision medicine of the future. In this article, we review current knowledge regarding biomarkers in difficult-to-treat asthma and their ability to guide the use of both conventional asthma therapies and novel (targeted) therapies. Biomarkers (as measured by tests including prednisolone and cortisol assays and the fractional exhaled nitric oxide (NO) suppression test) show promise in the assessment and management of non-adherence to inhaled and oral corticosteroids. Multiple markers of type 2 inflammation have been developed, including eosinophils in sputum and blood, exhaled NO, serum IgE and periostin. Although these show potential in guiding the selection of novel interventions for refractory type 2 inflammation in asthma, and in determining if the desired response is being achieved, it is becoming clear that different biomarkers reflect distinct components of the complex type 2 inflammatory pathways. Less progress has been made in identifying biomarkers for use in difficult-to-treat asthma that is not associated with type 2 inflammation. The future is likely to see further biomarker discovery, direct measurements of individual cytokines rather than surrogates of their activity and the increasing use of biomarkers in combination. If the promise of biomarkers is to be fulfilled, they will need to provide useful information that aids clinical decision-making, rather than being 'just another test' for clinicians to order.
引用
- Fricker M, Heaney LG, Upham JW, et al. Can biomarkers help us hit targets in difficult-to-treat asthma? Respirology. 2017. PMID: 28248008. doi:10.1111/resp.13014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。